Southern California Res. Ctr /ID# 265549, Coronado
UC San Diego Health System /ID# 265565, La Jolla
uc davis medical center - patient support services building /ID# 265554, Sacramento

RecruitingPhase 2

Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Smart Cures Clinical Research, Anaheim
Cedars-Sinai Medical Center, Beverly Hills
United Medical Doctors - Los Alamitos, Los Alamitos
and 1 more

RecruitingPhase 3

Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Alliance Research Institute-Site Number: 8400008, Canoga Park
Southern California GI & Liver Centers-Site Number: 8400062, Coronado
Gastroenterology and Liver Institute - Escondido-Site Number: 8400146, Escondido
and 14 more

RecruitingPhase 3

Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

UCSF Benioff Children's Hospital - Oakland /ID# 258327, Oakland

RecruitingPhase 3

Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

University of California Davis Comprehensive Cancer Center, Sacramento

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Biopharma Informatic, LLC, Los Angeles
Om Research LLC, Oxnard

RecruitingPhase 2

Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483073

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Biopharma Informatic, LLC, Los Angeles
Om Research LLC, Oxnard

RecruitingPhase 2

Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483099

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

UCSF Medical Center at Mission Bay, San Francisco

RecruitingPhase 3

Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Gastro Care Institute, Lancaster
Infinity Clinical Research, San Diego

RecruitingPhase 2

Ages 18 to 85 · All sexes · Updated Sep 22, 2026 · NCT06226883

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

University of California San Diego Health (UCSD), La Jolla
Cedars-Sinai Medical Center, Los Angeles
Hoag Hospital Newport Beach, Newport Beach

RecruitingPhase 4

Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Clinnova Research, Anaheim
Gastro SB Clinic, Chula Vista
United Medical Doctors, Los Alamitos
and 1 more

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577843

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Cedars Sinai Medical Center, Los Angeles

RecruitingPhase 3

Ages 2 to 17 · All sexes · Updated Aug 24, 2026 · NCT05509777

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Hoag Hospital, Irvine
UC San Diego Health, La Jolla
Cedars-Sinai, Los Angeles
and 1 more

Recruiting

Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Children's Hospital Of Orange County, Orange

RecruitingPhase 3

Ages 2 to 17 · All sexes · Updated Aug 3, 2026 · NCT06100289

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

UCSF Benioff Children's Hospital - Oakland /ID# 262217, Oakland
Lucile Packard Children's Hospital /ID# 262193, Palo Alto

RecruitingPhase 3

Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Loma Linda University, Loma Linda
Children's Hospital of Orange County, Orange
Stanford Children's Health, Palo Alto

RecruitingPhase 3

Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Cedars-Sinai Medical Center, Beverly Hills

RecruitingPhase 2

Ages 18 to 80 · All sexes · Updated Jun 5, 2026 · NCT06976853

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Cedars-Sinai, Los Angeles
UCSF Benioff Children's Hospitals, San Francisco

RecruitingPhase 4

Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

UCSD Medical Center, La Jolla
Keck Medicine Of USC - USC Healthcare Center 1, Los Angeles

RecruitingPhase 3

Ages 18 to 65 · All sexes · Updated May 27, 2026 · NCT06227910

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Rady Children's Hospital - San Diego - PIN, San Diego

RecruitingPhase 3

Ages 2 and older · All sexes · Updated May 7, 2026 · NCT05442567

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Rady Childrens Hospital San Diego - PIN, San Diego

RecruitingPhase 3

Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320

Precise Infliximab Exposure and Pharmacodynamic Control

Children's Hospital of Los Angeles, Los Angeles
Lucile Packard Children's Hospital Stanford, Palo Alto
Rady Children's Hospital San Diego, San Diego

RecruitingPhase 2/3

Ages 6 to 22 · All sexes · Updated May 5, 2026 · NCT05660746

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Hoag Hospital, Irvine
United Medical Doctors, Murrieta

RecruitingPhase 2

Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

Investigational Site Number: 8400005, Escondido
Investigational Site Number: 8400001, Lancaster

RecruitingPhase 2

Ages 18 to 75 · All sexes · Updated Mar 27, 2026 · NCT06958536

Effect of Statins on Crohn's Disease

Stanford University, Stanford

RecruitingEarly phase 1

Ages 18 to 80 · All sexes · Updated Feb 27, 2026 · NCT06538649

Impact of Prebiotics in Ulcerative Colitis

UCLA, Los Angeles

Recruiting

Ages 18 to 85 · All sexes · Updated Feb 27, 2026 · NCT06495658

Stem Cell Transplantation in Crohn's Disease

Cedars-Sinai Medical Center, Los Angeles

RecruitingPhase 1/2

Ages 13 to 28 · All sexes · Updated Feb 20, 2026 · NCT04224558

Treatment of Moderate to Severe Refractory Crohn's Disease

University of California, Davis, Sacramento
University of California, San Francisco, San Francisco

RecruitingPhase 1/2

Ages 18 to 65 · All sexes · Updated Dec 10, 2025 · NCT06721962

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

University of California, San Diego, La Jolla

RecruitingObservational study

All ages · Women · Updated Jan 28, 2025 · NCT02103361

Urine Metabolites in the Diagnosis of Disease

Unio Health Partners (Gastroenterology), Encinitas
Digestive Health Associates, Santa Monica
Westside Gastro Care, Santa Monica
and 1 more

RecruitingObservational studyHealthy volunteers welcome

Ages 18 and older · All sexes · Updated Dec 13, 2024 · NCT06710067

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.